Mass spectrometry-based proteomics for biomarker discovery in the Drosophila model of Parkinson's disease  

作　　者：Mohammad Radid Khan Ramisha A.Rahman Md Harunur Rashid Md Shariful Islam 

机构地区：[1]Department of Biochemistry and Microbiology,North South University,Dhaka,Bangladesh [2]Department of Pharmaceutical Sciences,North South University,Dhaka,Bangladesh [3]Department of Mathematics&Physics,North South University,Dhaka,Bangladesh [4]Department of Chemistry and Biochemistry,New Mexico State University,Las Cruces,New Mexico,USA

出　　处：《Neuroprotection》2024年第4期276-287,共12页神经保护(英文)

基　　金：supported by NSUCTRG Research Grant(2021-2022)(CTRG-21-SEPS-11);NSU CTRGResearch Grant(2022-2023)(CTRG-23-SEPS-14).

摘　　要：Parkinson's disease(PD)is the second most prevalent neurodegenerative disorder worldwide.Despite extensive research,the etiology of both familial and sporadic PD remains unclear.While most PD cases are sporadic,a significant minority are linked to genetic mutations,notably in the synuclein-alpha(SNCA)and leucine-rich repeat kinase 2(LRRK2)genes.Animal models,such as Drosophila melanogaster(D.melanogaster),enable detailed study of these genetic mutations and their neurotoxic effects.Recent advancements in mass spectrometry-based proteomics have enhanced our understanding of PD by facilitating comprehensive analysis of protein expression and interactions in mutant and wild-type organisms,potentially revealing novel therapeutic targets.This review highlights the pivotal role of mass spectrometry-based proteomics in advancing PD research,emphasizing the contributions of D.melanogaster models in identifying potential biomarkers.

关 键 词：biomarker discovery DROSOPHILA mass spectrometry Parkinson's disease PROTEOMICS 

分 类 号：R74[医药卫生—神经病学与精神病学]